Introducing
Prof Tomas Kalincik
Hello, I’m Tomas, Head of the Clinical Outcomes Research (CORe) Unit.
a little bit about me
I am the Head of the CORe Unit at the University of Melbourne, as well as the Head of the Multiple Sclerosis and Neuroimmunology Service at the Royal Melbourne Hospital.
Together with the CORe team, I specialise in analytics of observational data in neurology. I am an active participant in the global MSBase collaboration, undertaking a role in the MSBase Scientific Leadership Group.
My research interests revolve around disease outcomes in multiple sclerosis and Neuromyelitis Optica. These comprise comparative treatment effectiveness, management of treatment failure, individual treatment response, personalised therapy, prognostics, epidemiology and utility of volumetric MRI.
Publications
- Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression
- Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement
- Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis
- Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis
- The prevalence of epileptic seizures in multiple sclerosis in a large tertiary hospital in Australia
- Prognostic value of acute cerebrospinal fluid abnormalities in antibody-positive autoimmune encephalitis
- Peripheral Immune Cell Ratios and Clinical Outcomes in Seropositive Autoimmune Encephalitis: A Study by the Australian Autoimmune Encephalitis Consortium
- Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS
- Literature Commentary
- Effect of lateral therapy switches to oral moderate-efficacy drugs in multiple sclerosis: a nationwide cohort study
- Has the Time Come to Revisit Our Standard Measures of Disability Progression in Multiple Sclerosis?
- Correction to: Serum microRNA is a biomarker for post-operative monitoring in glioma
- Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a
- Comparative effectiveness of rituximab in multiple sclerosis
- Serum microRNA is a biomarker for post-operative monitoring in glioma
- COVID-19 in people with multiple sclerosis: A global data sharing initiative
- Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score
- Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy
- Aggressive multiple sclerosis (1): Towards a definition of the phenotype
- Aggressive multiple sclerosis (2): Treatment
- The MSReactor computerized cognitive battery correlates with the processing speed test in relapsing-remitting multiple sclerosis
- Monitoring of radiologic disease activity by serum neurofilaments in MS
- Correction to: Comparison of the effectiveness of a tailored cognitive behavioural therapy with a supportive listening intervention for depression in those newly diagnosed with multiple sclerosis (the ACTION-MS trial): protocol of an assessor-blinded, active comparator, randomised controlled trial
- Presentation and outcome of patients with intracranial tuberculoma in a high HIV prevalence setting
- Comparison of the effectiveness of a tailored cognitive behavioural therapy with a supportive listening intervention for depression in those newly diagnosed with multiple sclerosis (the ACTION-MS trial): protocol of an assessor-blinded, active comparator, randomised controlled trial
- Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder
- Psychometric properties of the Hospital Anxiety and Depression Scale in an inpatient video-monitoring epilepsy cohort
- Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype
- Head-to-head drug comparisons in multiple sclerosis: Urgent action needed
- PACS Integration of Semiautomated Imaging Software Improves Day-to-Day MS Disease Activity Detection
- Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination
- Real-world studies provide reliable comparisons of disease modifying therapies in MS - Yes
- Risk of secondary progressive multiple sclerosis: A longitudinal study
- Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis
- The feasibility, reliability and concurrent validity of the MSReactor computerized cognitive screening tool in multiple sclerosis
- The MSBase registry: Informing clinical practice
- Effectiveness of oral multiple sclerosis therapies in clinical context
- Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis
- Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy
- Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study
- Where there is inflammation, treatment may reduce disability progression - Yes
- Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosis
- Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis
- Comparisons of therapies in different scenarios help complete the puzzle
- Reply: Towards personalized therapy for multiple sclerosis: limitations of observational data
- Cognitive clinico-radiological paradox in early stages of multiple sclerosis
- Towards personalized therapy for multiple sclerosis: prediction of individual treatment response
- Corrigendum
- Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis
- Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS